These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 25672568)

  • 1. Comparative effectiveness of high-dose versus standard-dose influenza vaccines in US residents aged 65 years and older from 2012 to 2013 using Medicare data: a retrospective cohort analysis.
    Izurieta HS; Thadani N; Shay DK; Lu Y; Maurer A; Foppa IM; Franks R; Pratt D; Forshee RA; MaCurdy T; Worrall C; Howery AE; Kelman J
    Lancet Infect Dis; 2015 Mar; 15(3):293-300. PubMed ID: 25672568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative effectiveness of high-dose versus standard-dose influenza vaccination on numbers of US nursing home residents admitted to hospital: a cluster-randomised trial.
    Gravenstein S; Davidson HE; Taljaard M; Ogarek J; Gozalo P; Han L; Mor V
    Lancet Respir Med; 2017 Sep; 5(9):738-746. PubMed ID: 28736045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of high-dose versus standard-dose inactivated influenza vaccine in adults aged 65 years and older: an economic evaluation of data from a randomised controlled trial.
    Chit A; Becker DL; DiazGranados CA; Maschio M; Yau E; Drummond M
    Lancet Infect Dis; 2015 Dec; 15(12):1459-66. PubMed ID: 26362172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Age on Relative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries Aged ≥65 Years.
    Lu Y; Chillarige Y; Izurieta HS; Wei Y; Xu W; Lu M; Sung HM; Lindaas A; Wernecke M; Macurdy T; Kelman J; Forshee RA
    J Infect Dis; 2019 Sep; 220(9):1511-1520. PubMed ID: 31290553
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Effectiveness of High-Dose Versus Standard-Dose Influenza Vaccines Among US Medicare Beneficiaries in Preventing Postinfluenza Deaths During 2012-2013 and 2013-2014.
    Shay DK; Chillarige Y; Kelman J; Forshee RA; Foppa IM; Wernecke M; Lu Y; Ferdinands JM; Iyengar A; Fry AM; Worrall C; Izurieta HS
    J Infect Dis; 2017 Feb; 215(4):510-517. PubMed ID: 28329311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of high-dose versus standard-dose influenza vaccination in community-dwelling veterans.
    Richardson DM; Medvedeva EL; Roberts CB; Linkin DR;
    Clin Infect Dis; 2015 Jul; 61(2):171-6. PubMed ID: 25829001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin Use and Risks of Influenza-Related Outcomes Among Older Adults Receiving Standard-Dose or High-Dose Influenza Vaccines Through Medicare During 2010-2015.
    Izurieta HS; Chillarige Y; Kelman JA; Forshee R; Qiang Y; Wernecke M; Ferdinands JM; Lu Y; Wei Y; Xu W; Lu M; Fry A; Pratt D; Shay DK
    Clin Infect Dis; 2018 Jul; 67(3):378-387. PubMed ID: 29438483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative Effectiveness of Cell-Cultured and Egg-Based Influenza Vaccines Among Elderly Persons in the United States, 2017-2018.
    Izurieta HS; Chillarige Y; Kelman J; Wei Y; Lu Y; Xu W; Lu M; Pratt D; Chu S; Wernecke M; MaCurdy T; Forshee R
    J Infect Dis; 2019 Sep; 220(8):1255-1264. PubMed ID: 30561688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cluster randomized controlled trial comparing relative effectiveness of two licensed influenza vaccines in US nursing homes: Design and rationale.
    Gravenstein S; Dahal R; Gozalo PL; Davidson HE; Han LF; Taljaard M; Mor V
    Clin Trials; 2016 Jun; 13(3):264-74. PubMed ID: 26908539
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relative vaccine effectiveness of MF59-adjuvanted vs high-dose trivalent inactivated influenza vaccines for prevention of test-confirmed influenza hospitalizations during the 2017-2020 influenza seasons.
    McGovern I; Chastek B; Bancroft T; Webb N; Imran M; Pelton SI; Haag MDM
    Int J Infect Dis; 2024 Sep; 146():107160. PubMed ID: 38969330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative Effectiveness of Influenza Vaccines Among US Medicare Beneficiaries Ages 65 Years and Older During the 2019-2020 Season.
    Izurieta HS; Lu M; Kelman J; Lu Y; Lindaas A; Loc J; Pratt D; Wei Y; Chillarige Y; Wernecke M; MaCurdy TE; Forshee R
    Clin Infect Dis; 2021 Dec; 73(11):e4251-e4259. PubMed ID: 33211809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relative Effectiveness of Influenza Vaccines Among the United States Elderly, 2018-2019.
    Izurieta HS; Chillarige Y; Kelman J; Wei Y; Lu Y; Xu W; Lu M; Pratt D; Wernecke M; MaCurdy T; Forshee R
    J Infect Dis; 2020 Jun; 222(2):278-287. PubMed ID: 32100009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study.
    Heinonen S; Silvennoinen H; Lehtinen P; Vainionpää R; Ziegler T; Heikkinen T
    Lancet Infect Dis; 2011 Jan; 11(1):23-9. PubMed ID: 21106443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose inactivated influenza vaccine is associated with cost savings and better outcomes compared to standard-dose inactivated influenza vaccine in Canadian seniors.
    Becker DL; Chit A; DiazGranados CA; Maschio M; Yau E; Drummond M
    Hum Vaccin Immunother; 2016 Dec; 12(12):3036-3042. PubMed ID: 27669017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relative Effectiveness of Adjuvanted Trivalent Inactivated Influenza Vaccine Versus Egg-derived Quadrivalent Inactivated Influenza Vaccines and High-dose Trivalent Influenza Vaccine in Preventing Influenza-related Medical Encounters in US Adults ≥ 65 Years During the 2017-2018 and 2018-2019 Influenza Seasons.
    Boikos C; Fischer L; O'Brien D; Vasey J; Sylvester GC; Mansi JA
    Clin Infect Dis; 2021 Sep; 73(5):816-823. PubMed ID: 33605977
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older.
    Pillsbury AJ; Fathima P; Quinn HE; Cashman P; Blyth CC; Leeb A; Macartney KK
    JAMA Netw Open; 2020 May; 3(5):e204079. PubMed ID: 32369177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-label and off-label use of high-dose influenza vaccine in the United States, 2010-2012.
    McGrath LJ; Brookhart MA
    Hum Vaccin Immunother; 2015; 11(3):537-44. PubMed ID: 25751700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of serious events in adults 65 years of age or older: A comparison between high-dose and standard-dose inactivated influenza vaccines.
    DiazGranados CA; Robertson CA; Talbot HK; Landolfi V; Dunning AJ; Greenberg DP
    Vaccine; 2015 Sep; 33(38):4988-93. PubMed ID: 26212007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cohort study of the effectiveness of influenza vaccine in older people, performed using the United Kingdom general practice research database.
    Mangtani P; Cumberland P; Hodgson CR; Roberts JA; Cutts FT; Hall AJ
    J Infect Dis; 2004 Jul; 190(1):1-10. PubMed ID: 15195237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.